Please ensure Javascript is enabled for purposes of website accessibility

No More Tears, Far More Fears?

By Brian Orelli, PhD – Updated Apr 6, 2017 at 2:38AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sorry, China -- carcinogens in baby shampoo don't equal lead in toys.

It looks like China's answer to sending us contaminated toothpaste, tainted ingredients that Baxter (NYSE:BAX) eventually made into heparin, and toys with lead paint on them sold by RC2 (NASDAQ:RCRC) and Mattel (NYSE:MAT), is to respond with a childish, "I'm rubber, you're glue; everything bounces off of me and sticks to you."

This week, China's Food and Drug Administration said that it's investigating products made by our beloved Johnson & Johnson (NYSE:JNJ), after a U.S. group reported that there may be carcinogens in J&J's baby shampoo. Big deal? Frankly, no.

You see, carcinogens are everywhere. Some are manmade, but there are also natural carcinogens in the food we eat: broccoli, nutmeg, peaches, and radishes, for instance. (Kids around the world rejoice: No more broccoli!) You'll even find them in tasty drinks. It's the concentration that's important -- in this case, size (or amount) does matter. Johnson & Johnson reports that there are just "trace levels" in the shampoo.

I can see how China might be on edge after finding toxic melamine in baby formula, but this seems a little blown out of proportion. I'd liken it to biotech corn ending up in Kellogg (NYSE:K) cereal and Yum! Brands' (NYSE:YUM) Taco Bell tacos. It's highly unlikely that the shampoo will hurt anyone, but it's still a public relations nightmare.

Johnson & Johnson handled the Tylenol contamination in the 1980s -- which wasn't the company's fault -- quite well. But for minor public relation issues, it's had a few missteps recently. It sued the beloved Red Cross because it uses the same trademark, and its Motrin-moms advertising campaign created enough of a negative reaction that it had to pull the ad. Those public relation blunders don't get you very high marks with consumers.

And that should be the big worry here for investors. Not that the shampoo is contaminated, but that merely hearing the word "cancer" will be enough to cause consumers in China and the U.S. to look elsewhere. Johnson & Johnson needs to nip this one in the bud, pronto.

Lather, rinse, repeat to further Foolishness:

  • Sell this tech stock now.
  • These seven great American stocks are on sale.
  • These stocks are cheaper than they appear.

RC2 is a Motley Fool Hidden Gems selection. Johnson & Johnson is a Income Investor pick. Whether you like your companies big or small, dividend-laden or with "multibagger" written all over them, we've got a newsletter for you.

Having handled carcinogens in the laboratory, Fool contributor Brian Orelli, Ph.D., is well aware that concentration does matter. He doesn't own shares of any company mentioned in this article. The Fool's disclosure policy won't sting your eyes.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$165.70 (-0.61%) $-1.02
Yum! Brands, Inc. Stock Quote
Yum! Brands, Inc.
YUM
$109.16 (-1.35%) $-1.49
Kellogg Company Stock Quote
Kellogg Company
K
$72.93 (-0.15%) $0.11
Mattel, Inc. Stock Quote
Mattel, Inc.
MAT
$19.71 (-0.95%) $0.19
Baxter International Inc. Stock Quote
Baxter International Inc.
BAX
$54.91 (-0.90%) $0.50
TOMY International, Inc. Stock Quote
TOMY International, Inc.
RCRC

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.